Datroway savings card: as little as $0 an infusion with commercial insurance

Datroway is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Datroway is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameDatroway

Authorized genericdatopotamab deruxtecan

Regular genericdatopotamab deruxtecan

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Datroway?

The original

–

Brand nameThe maker’s card

DATROWAY Patient Savings Program (DATROWAY4U)

Savings card from Daiichi Sankyo

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 an infusion

Or call 1-833-904-1851.

In the maker’s words

“Eligible patients with a valid prescription for DATROWAY may pay as little as $0 per infusion and $0 out-of-pocket costs for DATROWAY.”

From the maker’s offer on datroway4u.com, checked October 27, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Datroway itself, from the same company, sold without the brand name, and usually for less. For now Datroway is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Datroway is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of:

adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.

Source: the FDA label for Datroway (Daiichi Sankyo Inc.), May 27, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked October 27, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/datroway/